ATE137958T1 - Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen - Google Patents

Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen

Info

Publication number: ATE137958T1
Authority: AT; Austria
Prior art keywords: prophylaxis; treatment; viral diseases; pharmaceutical aerosol; aerosol preparation
Prior art date: 1991-08-21

Application number

AT92919013T

Other languages

English (en)

Inventor

Oleg Petrovich Zhirnov

Alexandr Valentinov Ovcharenko

Original Assignee

Oleg Petrovich Zhirnov

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-21

Filing date

1992-08-19

Publication date

1996-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21584787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE137958(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-08-19 Application filed by Oleg Petrovich Zhirnov filed Critical Oleg Petrovich Zhirnov

1996-06-15 Application granted granted Critical

1996-06-15 Publication of ATE137958T1 publication Critical patent/ATE137958T1/de

Links

238000011321 prophylaxis Methods 0.000 title abstract 2
238000011282 treatment Methods 0.000 title abstract 2
230000003612 virological effect Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000008249 pharmaceutical aerosol Substances 0.000 title 1
239000013543 active substance Substances 0.000 abstract 2
239000007864 aqueous solution Substances 0.000 abstract 2
108010039627 Aprotinin Proteins 0.000 abstract 1
229960004405 aprotinin Drugs 0.000 abstract 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT92919013T 1991-08-21 1992-08-19 Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen ATE137958T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SU5000531/14A RU2054180C1 (ru)	1991-08-21	1991-08-21	Способ лечения вирусных респираторных инфекций

Publications (1)

Publication Number	Publication Date
ATE137958T1 true ATE137958T1 (de)	1996-06-15

Family

ID=21584787

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92919013T ATE137958T1 (de)	1991-08-21	1992-08-19	Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen

Country Status (9)

Country	Link
US (1)	US5723439A (de)
EP (1)	EP0563389B1 (de)
JP (1)	JP2774379B2 (de)
AT (1)	ATE137958T1 (de)
AU (1)	AU2517792A (de)
DE (1)	DE69210802T2 (de)
DK (1)	DK0563389T3 (de)
RU (1)	RU2054180C1 (de)
WO (1)	WO1993003708A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99864A (en) *	1990-10-31	2000-11-21	Autoimmune Inc	Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
NZ271181A (en) *	1993-07-19	1998-06-26	Amgen Inc	Protein protection; method for stabilising aerosolised proteins by adding a water-soluble polar organic compound to the aqueous solution prior to aerosolisation
JP3469584B2 (ja)	1996-03-11	2003-11-25	バイエルコーポレイション	ヒトビクニン
RU2140273C1 (ru) *	1996-11-06	1999-10-27	Закрытое акционерное общество "АЭРОМЕД"	Способ лечения простудных заболеваний
DE19830694A1 (de) *	1998-07-09	2000-01-13	Bayer Ag	Substituierte Acylaminophenyl-uracile
ES2209542T3 (es) *	1998-12-22	2004-06-16	Bayer Aktiengesellschaft	Metodo para acelerar la velocidad de eliminacion mucociliar usando un inhibidor de serinproteasa de tipo kunitz.
DE10141749A1 (de) *	2000-08-29	2002-03-14	Max Delbrueck Centrum	Mittel zur Beeinflussung der Angiogenese
WO2003035030A1 (en) *	2001-10-24	2003-05-01	Pari Gmbh	Kit for the preparation of a pharmaceutical composition
US8512710B2 (en)	2002-11-22	2013-08-20	Ansun Biopharma, Inc.	Class of therapeutic protein based molecules
US7807174B2 (en)	2002-11-22	2010-10-05	Nexbio, Inc.	Class of therapeutic protein based molecules
CA2506526C (en)	2002-11-22	2017-04-18	Mang Yu	Broad spectrum anti-viral therapeutics and prophylaxis
MD3381G2 (ro) *	2006-06-19	2008-03-31	Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова	Metodă de tratament al parotiditei cronice la copii
EP2371857A1 (de) *	2010-04-01	2011-10-05	CSL Behring GmbH	Faktor-XII-Inhibitoren zur Behandlung von interstitieller Pneumonie
RU2425691C1 (ru)	2010-07-15	2011-08-10	ВАКЕ спол с.р.о.	Аэрозольный препарат на основе апротинина для лечения вирусных респираторных инфекций
EP2714716B1 (de) *	2011-06-02	2018-04-11	Socpra Sciences Santé Et Humaines S.E.C.	Matriptase-hemmer und verwendungen davon gegen orthomyxoviridae-infektionen
RU2657523C2 (ru) *	2011-11-03	2018-06-14	Олег Петрович Жирнов	Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение
DE202012013134U1 (de)	2012-11-01	2014-12-05	Oleg Petrovich Zhirnov	Pharmazeutische Aerosolformulierung von Protease-Inhibitoren und deren Zubereitung
TW201427681A (zh)	2013-01-07	2014-07-16	Superlab Far East Ltd	用空間構象改變的重組干擾素治療腫瘤的方法
RU2711080C2 (ru) *	2015-06-15	2020-01-15	Олег Петрович Жирнов	Комбинированный аэрозольный состав на основе ингибиторов протеаз и его получение
RU2738885C1 (ru) *	2020-04-30	2020-12-18	Андрей Александрович Иващенко	Противо-SARS-CoV-2 вирусное средство Антипровир
US20220000993A1 (en) *	2020-07-06	2022-01-06	Torvald Ranta Foretagsjuridik AB	Drug for use against the novel coronavirus disease, covid-19
US20240415944A1 (en) *	2021-04-06	2024-12-19	Andrey Alexandrovich Ivashchenko	Aqueous aprotinin-containing antiviral pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE556587A (de) *	1957-01-31	1957-04-11
DE2654124A1 (de) *	1976-11-29	1978-06-01	Bayer Ag	Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
CA1178889A (en) *	1980-08-28	1984-12-04	Kenneth S. Su	Intranasal formulation
DE3175003D1 (en) *	1981-06-25	1986-08-28	Serapharm Gmbh & Co Kg	Enriched plasma derivative for promoting wound sealing and wound healing
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US5262157A (en) *	1987-03-26	1993-11-16	Sloan-Kettering Institute For Cancer Research	Method of preventing Pneumocystis carinii pneumonia using pentamidine in an aerosol form
JP2656944B2 (ja) *	1987-04-30	1997-09-24	クーパーラボラトリーズ	タンパク質性治療剤のエアロゾール化
JP2804979B2 (ja) *	1988-11-28	1998-09-30	日本ケミカルリサーチ株式会社	エイズ治療および阻害剤
FR2646354B1 (fr) *	1989-04-27	1994-06-10	Sanofi Sa	Utilisation de peptides inhibiteurs de proteases acides pour la preparation de medicaments utiles pour le traitement de maladies virales
CS275231B2 (en) *	1989-09-29	1992-02-19	Ustav Makormolekularni Chemie	Medicine bottle
DE4117078A1 (de) *	1991-05-25	1992-11-26	Boehringer Ingelheim Kg	Verfahren zur herstellung therapeutisch anwendbarer aerosole

1991
- 1991-08-21 RU SU5000531/14A patent/RU2054180C1/ru active
1992
- 1992-08-19 AU AU25177/92A patent/AU2517792A/en not_active Abandoned
- 1992-08-19 WO PCT/RU1992/000164 patent/WO1993003708A1/ru not_active Ceased
- 1992-08-19 US US08/039,393 patent/US5723439A/en not_active Expired - Lifetime
- 1992-08-19 DE DE69210802T patent/DE69210802T2/de not_active Expired - Lifetime
- 1992-08-19 EP EP92919013A patent/EP0563389B1/de not_active Expired - Lifetime
- 1992-08-19 JP JP5504250A patent/JP2774379B2/ja not_active Expired - Lifetime
- 1992-08-19 DK DK92919013.0T patent/DK0563389T3/da active
- 1992-08-19 AT AT92919013T patent/ATE137958T1/de active

Also Published As

Publication number	Publication date
WO1993003708A1 (fr)	1993-03-04
JP2774379B2 (ja)	1998-07-09
DE69210802T2 (de)	1997-01-16
AU2517792A (en)	1993-03-16
EP0563389B1 (de)	1996-05-15
DE69210802D1 (de)	1996-06-20
JPH06506474A (ja)	1994-07-21
US5723439A (en)	1998-03-03
RU2054180C1 (ru)	1996-02-10
DK0563389T3 (da)	1996-09-30
EP0563389A1 (de)	1993-10-06
EP0563389A4 (en)	1993-10-20

Legal Events

Date	Code	Title	Description
1997-01-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE137958T1 (de)	1996-06-15	Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen
TW329387B (en)	1998-04-11	Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
ATE401093T1 (de)	2008-08-15	Extrakte, wirkstoffe und pharmazeutische präparate mit antidiabetischen eigenschaften und ihre verwendung
ATE128350T1 (de)	1995-10-15	Pharmazeutische aerosolformulierung.
GEP20002298B (en)	2000-11-25	Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
GR3032207T3 (en)	2000-04-27	2-Bromomelatonin in the therapy of sleep disorders
UA41502C2 (uk)	2001-09-17	Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
EE03222B1 (et)	1999-10-15	Inhaleeritavad ravimpreparaadid, protsess nende valmistamiseks ja seade nende kasutamiseks
ATE77947T1 (de)	1992-07-15	Pentamidin enthaltende pharmazeutische zusammensetzungen.
WO1994008551A3 (en)	1994-06-23	Pharmaceutical compositions and methods for treating cold symptoms
IL101056A (en)	1997-03-18	Composition for nasal treatment
ATE99172T1 (de)	1994-01-15	Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
GR3015052T3 (en)	1995-05-31	Antibiotic GE 2270 factors A1, A2, A3 and H.
DK0533896T3 (de)	1997-02-17
ATE81981T1 (de)	1992-11-15	Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe.
ATE106732T1 (de)	1994-06-15	Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
AU1494395A (en)	1995-09-28	The use of deoxyspergualin for preparing a pharmaceutical for treating hyperreactive inflammatory diseases
JPS6422805A (en)	1989-01-25	Aerosol germicide composition
ATE124041T1 (de)	1995-07-15	Nitrofurantoinkristalle.
DE69427949D1 (de)	2001-09-20	Acriflavine enthaltende Arzneimittel verwendbar zur Behandlung von Herpes und Zona
DE60202299D1 (de)	2005-01-20	Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
ATE70443T1 (de)	1992-01-15	Pharmazeutische zusammensetzung.
UA19158A (uk)	1997-12-25	Спосіб лікуваhhя вірусhих респіраторhих іhфекцій
DE69116452D1 (de)	1996-02-29	Verwendung von 3-Oxygermylpropionsäure zur Behandlung des Erkältungssyndroms
TH19526A (th)	1996-07-16	วิธีการและสารผสมสำหรับรักษาโรคตับอักเสบชนิดออโตอิมมูน